Resources for Patients
The administration of CCP is rapidly evolving and this information is provided by AABB with the intent of helping patients to understand options and considerations for the use of CCP as an investigational treatment. The decision to receive CCP is one that patients or their loved ones should make in consultation with the patient’s physician.
How can patients with COVID-19 get CCP?
Patients with COVID-19 may be able to receive treatment with CCP. If the hospital where you are being treated does not know how to access CCP, please encourage your physician to visit the Resources for Clinicians section of this site.
Is convalescent plasma transfusion safe?
- If you or someone you know is being treated for COVID-19, your doctors may determine that CCP transfusion is an appropriate treatment option to consider. You should discuss this option with your doctor to understand if it is the best treatment option for you.
- Plasma transfusion is generally considered a low-risk treatment but it is not free of risk. Each donation undergoes extensive testing and processing for safety and quality as required by AABB and the FDA. Early research into the use of CCP suggests that it may be a safe and effective therapy that reduces the length and severity of COVID-19. AABB-accredited hospitals have chosen to meet voluntary quality and safety standards as part of their commitment to patient safety.
- The Mayo Clinic coordinated the largest safety study to date of CCP transfusion, covering tens of thousands of patients; their results consistently found that the risks associated with CCP transfusion are no different than those for transfusion of plasma.
Is Convalescent Plasma Transfusion an Effective Treatment for COVID-19?
There is not yet a definitive answer. Several studies have not found a benefit of CCP transfusion, but many of those studies either used CCP that contained an insufficient quantity of antibodies or assessed patients with advanced disease. For CCP to be effective in reducing mortality and preventing or shortening hospitalizations, as was demonstrated by a randomized controlled trial in Argentina, it may be necessary to give the treatment early in the disease course.
At the same time, AABB has assembled a panel of experts to review all of the scientific literature on CCP. The group will finalize this work later this year, but they have already issued some preliminary recommendations.
For FDA’s most current information for patients, refer to the Fact Sheet for Patients and Parents/Caregivers: EUA of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Hospitalized Patients, (updated Feb 04 2021)